Shots:
- GSK & Shionogi, together with Pfizer, have agreed to replace Pfizer’s 11.7% economic interest in ViiV Healthcare with an investment by Shionogi, reshaping the ownership structure of ViiV Healthcare
- As per the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125B, cancel Pfizer’s stake, pay Pfizer $1.875B, & distribute a $0.25B special dividend to GSK (payable in GBP); closing expected in Q1’26
- Following the transaction, Shionogi will increase its economic interest in ViiV Healthcare to 21.7%, while GSK will retain its majority stake with a 78.3% economic interest
Ref: GSK | Image: GSK, Shionogi, Pfizer & ViiV Healthcare | Press Release
Related News: Pfizer Signs ~$530M Deal to Use Novavax’s Adjuvant in Product Development
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
